Zelira Therapeutics Ltd
Research Zelira Therapeutics Ltd (ZLD) on Bullrun: market cap AUD 6.57M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZLD
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 6.57M
- Financial periodFY2025
- RevenueAUD 656
- Revenue growth-99.3%
- Net income-AUD 3.63M
- Free cash flow-AUD 4.91M
- Gross margin-1245.4%
Valuation Snapshot
latest market cap is AUD 6.57M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 656 | -AUD 3.63M | -AUD 4.91M | -1245.4% | -0.32 | AUD 5.66K | AUD 2.14M | -AUD 4.46M |
| FY2024 | AUD 94.95K | -AUD 36.57M | -AUD 4.39M | 10.8% | -3.22 | AUD 586.16K | AUD 5.95M | -AUD 4.51M |
| FY2023 | AUD 301.12K | -AUD 5.57M | -AUD 7.25M | -20.4% | -0.55 | AUD 146.21K | AUD 437.90K | AUD 31.80M |
| FY2022 | AUD 1.54M | -AUD 11.95M | -AUD 9.43M | 39.0% | -1.54 | AUD 2.75M | AUD 500.91K | AUD 35.20M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | AUD 6.57M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Zelira Therapeutics Ltd
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Zelira Therapeutics Ltd's market cap?
Zelira Therapeutics Ltd's market capitalization is AUD 6.57M.
What does Zelira Therapeutics Ltd do?
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia.